Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study - sprookjes - yvandenbroek - TriplyDB

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

http://www.wikidata.org/entity/Q28610375

about

Abacavir pharmacogenetics--from initial reports to standard of care A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals Abacavir/lamivudine combination in the treatment of HIV: a review.Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.PharmGKB summary: abacavir pathway Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia Development and validation of the first liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium.Population pharmacokinetics of abacavir in infants, toddlers and children.Induction of P-glycoprotein by antiretroviral drugs in human brain microvessel endothelial cells.Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor abacavir + UDP-glucuronate => abacavir 5'-glucuronide + UDP

P2860

Q27008841-8A53B7F2-C1BD-4D82-9926-591C1E443D6F Q27692040-DCED087E-0E1A-4D1B-8CD9-E959EB9E7546 Q28069383-CEE4FAF8-D422-45A2-BD4F-E5D4F84B27CB Q33715435-05AC521E-8E3D-4F44-A120-76C7FF4FF58B Q33786313-FDBD7BD8-F2E3-4D65-999A-C60A2149FC3B Q33819062-76698469-FE59-4B03-B0C3-F6F8D4D5B435 Q33836584-986BC271-F636-49B1-A27E-A95B5B0F9AD8 Q33980164-FE50FA32-42AC-4060-B2CA-3CDB5C1A1120 Q33980172-DC8E9B7C-4EE0-4693-A10A-02960E118666 Q34142328-3AE9C14E-4E6E-4FBB-ACDC-3FE60507909E Q35013781-CCD43B24-52B3-4969-9D17-76E1C3F7C5F6 Q35826691-CD1CCA54-8200-467F-B99F-66BF748B4AC6 Q35932561-995BD4AC-3C9A-4AD4-B60F-46A99B0E96EC Q36036400-6F13432D-BDB9-4E11-BBED-E827010D16AD Q36268156-F578A832-6B5D-42DA-90EF-1A69A837F924 Q36800100-EFE16557-6D05-476B-A2B2-3AD3E9B09B4F Q36948138-D76CA55A-B42F-4C9D-87AE-CB7D3102A2E3 Q37124197-D8ACA93E-F56F-4A00-933F-B89304556B8C Q37399199-A9AF4F65-6EB3-4910-955E-A777FBFBC001 Q40600560-D88C8E09-A20E-40FC-AD99-4FD74053E588 Q42769588-D7D73A9B-AE6F-4CB2-80DF-FDE5503A5B7B Q50295452-EDB39FA8-DAA4-4809-AB8D-76985BA2B96F

P2860

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

http://www.wikidata.org/entity/Q28610375

description

1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 1999

@ast

im Dezember 1999 veröffentlichter wissenschaftlicher Artikel

@de

scientific journal article

@en

vedecký článok (publikovaný 1999/12/01)

@sk

vědecký článek publikovaný v roce 1999

@cs

wetenschappelijk artikel (gepubliceerd op 1999/12/01)

@nl

наукова стаття, опублікована в грудні 1999

@uk

مقالة علمية (نشرت في ديسمبر 1999)

@ar

name

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@ast

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@en

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@nl

type

label

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@ast

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@en

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@nl

prefLabel

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@ast

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@en

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@nl

P1433

Q28610375-4E1D4316-D1F4-4723-92FE-B49051791892

P1476

Q28610375-B62C6527-5D9D-4C16-9D18-B893F7AC06A5

P2093

Q28610375-62D385D8-C661-4F58-859C-9F76727891E8

Q28610375-62D6E946-92DF-43FB-91CE-8FAD1F55D65C

Q28610375-6D11FB5B-3346-4FD1-A3C5-0A4E3D3AEF50

Q28610375-B3897412-4EEB-4DE6-A85D-A25104C98FBD

Q28610375-BB86AB39-DD3E-4FBE-A58E-B178B05D38FC

Q28610375-EFB3D871-9C31-45BE-8531-28004F804D39

P2860

Q28610375-02B3335D-9F00-4952-92AE-72DCAAFC5051

Q28610375-058B2B3A-861A-4B87-A21B-D86B716BCADC

Q28610375-34B47AB8-BDBC-42BA-B779-EC39FB13FD51

Q28610375-3E01651A-F2E1-4726-BBBE-908FA56459CA

Q28610375-45ADE520-BA78-49C5-8FBD-B5D8FF87EC7C

Q28610375-642E07B8-4525-436F-B382-AA3C2B2E276E

Q28610375-6B008384-966A-4845-9BA6-44D09E381684

Q28610375-8670E094-9B8A-4898-A9B2-F11C5982EF06

Q28610375-90F680AB-8F99-4708-B65F-2368DB27BB45

Q28610375-9B75492F-2F06-4610-B2F6-5259DB5F0F98

P304

Q28610375-8A6EC7AC-6671-4DEB-8DBA-3BAD60207F16

P31

Q28610375-F93BF2DF-229A-49FA-8603-4A088599BC28

P3181

Q28610375-151D4221-C3FA-458E-8B80-CCB9C0B537EA

P356

Q28610375-4BC1369F-A84F-4006-93D8-FEEF66D0397E

P407

Q28610375-5E31C288-46DB-4F93-9CB6-D9CCE0D926D7

P433

Q28610375-F539F2A1-586D-43B1-BDBF-679425564102

P478

Q28610375-03F9592E-DAB5-4CB6-AACB-F53C29A74C2C

P577

Q28610375-E7BF2E35-E4A4-4B74-A597-C320197BBCE2

P698

Q28610375-2537E41D-C9D6-4778-89FA-1808E1D15D3B

P921

Q28610375-0C1E66DB-7AB5-4769-B717-FDFBCFB87B4C

Q28610375-29E30F6F-B52A-405B-BA22-4F75CBC7960C

P932

Q28610375-D5D35498-A5B5-4132-87D3-CCDBE2E8FA32

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of [(14)C]aba ...... d adults: a mass balance study

@en

P2093

D S Stein

http://www.w3.org/2001/XMLSchema#string

G E Chittick

http://www.w3.org/2001/XMLSchema#string

J A McDowell

http://www.w3.org/2001/XMLSchema#string

J R Ravitch

http://www.w3.org/2001/XMLSchema#string

R E Polk

http://www.w3.org/2001/XMLSchema#string

T M Kerkering

http://www.w3.org/2001/XMLSchema#string

P2860

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.

P304

2855-2861

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3260068

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.43.12.2855

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10582871

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

89576

http://www.w3.org/2001/XMLSchema#string